Kingsley Tai Pharmaceutical-B (02511) fell more than 21%, reaching a new low of HKD 2.78, continuing to create a record low since listing. The stock has fallen more than 76% in the past six months since it was listed. As of the press time, it fell by 20.61% to HKD 2.85, with a turnover of HKD 11.6294 million.
According to the Wisdom Financial app, Kingsley Tai Pharmaceutical-B (02511) fell more than 21%, reaching a new low of HKD 2.78, continuing to create a record low since listing. The stock has fallen more than 76% in the past six months since it was listed. As of the press time, it fell by 20.61% to HKD 2.85, with a turnover of HKD 11.6294 million.
Kingsley Tai Pharmaceutical is a global integrated biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies with multiple functions and targets to treat metabolic and digestive system diseases. As of now, the company has not yet commercialized any products and has no revenue. Due to continuous large research and development investments, the company has been losing money in recent years. Data shows that in 2022 and 2023, Kingsley Tai Pharmaceutical's research and development investment will be RMB 183 million and RMB 312 million, respectively. During the same period, the adjusted net losses were RMB 184 million and RMB 288 million, respectively.
It's worth noting that according to the prospectus information disclosed by Kingsley Tai Pharmaceutical, the company's largest shareholder Hepalink has transferred 631,800 shares, 461,000 shares, and 371,700 shares to third parties in April, September, and October 2022, respectively, cashing a total of USD 7.8808 million.